The earnings call highlighted significant clinical progress, particularly with soquelitinib, and a strong cash position, offset by increased net loss and R&D expenses. The positive clinical data and financial stability indicate a promising outlook despite financial challenges.

Company Guidance -

Q3 2025

During the Corvus Pharmaceuticals second-quarter 2025 business update and financial results conference call, significant guidance was provided on various metrics concerning the company's financial and clinical progress. Research and development expenses increased to $7.9 million in Q2 2025 from $4.1 million in the same period in 2024, primarily due to soquelitinib development costs. The net loss for the quarter was $8 million, including a $400,000 noncash loss related to Angel Pharmaceuticals, with a noncash gain of $2 million from changes in Corvus' warrant liability. Stock compensation expense rose to $1.3 million from $800,000 a year earlier. Corvus reported cash, cash equivalents, and marketable securities totaling $74.4 million as of June 30, 2025. Key clinical updates included promising Phase I trial data for soquelitinib in atopic dermatitis, with a mean percent reduction in EASI score of 64.8% in Cohort 3. The company plans a Phase II trial with approximately 200 patients to assess different dosing regimens. Additionally, Corvus is advancing trials for soquelitinib in T-cell lymphoma and autoimmune lymphoproliferative syndrome, with ongoing efforts to explore next-generation ITK inhibitors.

Increased Cash Position

Corvus Pharmaceuticals increased its cash, cash equivalents, and marketable securities to $74.4 million as of June 30, 2025, compared to $52 million at December 31, 2024, partly due to common stock warrants exercise resulting in $35.7 million cash proceeds.

Encouraging Clinical Trial Results for Soquelitinib

The Phase I trial for soquelitinib in atopic dermatitis showed promising results, with Cohort 3 demonstrating a mean percent reduction of EASI score of 64.8% compared to 54.6% for previous cohorts and 34.4% for placebo. 50% of patients in Cohort 3 achieved EASI-75.

Advancement of Soquelitinib Clinical Trials

Corvus Pharmaceuticals is advancing soquelitinib with a planned Phase II trial for atopic dermatitis and an extension Cohort 4, continuing to demonstrate favorable safety and efficacy profiles.

Successful Completion of Stock Warrant Exercise

All remaining common stock warrants were exercised during the quarter, providing additional capital and demonstrating investor confidence.

Corvus Pharmaceuticals (CRVS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CRVS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.13 / -	-0.6	―	―	―
Aug 07, 2025	2025 (Q2)	-0.13 / -0.10	-0.07	-42.86% (-0.03)	―
May 08, 2025	2025 (Q1)	-0.12 / -0.13	-0.12	-8.33% (-0.01)
Mar 25, 2025	2024 (Q4)	-0.12 / -0.18	-0.14	-28.57% (-0.04)	―
Nov 12, 2024	2024 (Q3)	-0.11 / -0.60	-0.12	-400.00% (-0.48)	―
Aug 06, 2024	2024 (Q2)	-0.12 / -0.07	-0.14	50.00% (+0.07)	―
May 06, 2024	2024 (Q1)	-0.14 / -0.12	-0.17	29.41% (+0.05)	―
Mar 19, 2024	2023 (Q4)	-0.12 / -0.14	-0.21	33.33% (+0.07)	―
Nov 07, 2023	2023 (Q3)	-0.12 / -0.12	-0.32	62.50% (+0.20)	―
Aug 08, 2023	2023 (Q2)	-0.14 / -0.14	-0.18	22.22% (+0.04)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CRVS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$4.13	$4.31	+4.36%
May 08, 2025	$3.35	$4.43	+32.24%
Mar 25, 2025	$3.93	$3.35	-14.76%
Nov 12, 2024	$8.69	$8.87	+2.07%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Corvus Pharmaceuticals Inc (CRVS) report earnings?

Corvus Pharmaceuticals Inc (CRVS) is schdueled to report earning on Oct 30, 2025, TBA (Confirmed).

What is Corvus Pharmaceuticals Inc (CRVS) earnings time?

Corvus Pharmaceuticals Inc (CRVS) earnings time is at Oct 30, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CRVS EPS forecast?

CRVS EPS forecast for the fiscal quarter 2025 (Q3) is -0.13.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing